Overview Financials News + Filings Key Docs Ownership Insiders
|
|
Amylyx Pharmaceuticals, Inc.
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 |
| | 10-K | 8-K | 10-K | 8-K | S-1 | S-1/A |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Cost of goods sold | 13.5% | 80.8% | 0.0% | 99.4% | 161.2% | |
| Gross profit | 86.5% | 19.2% | 100.0% | 0.6% | -61.2% | |
| Selling, general and administrative | 571.9% | 109.9% | 13660.7% | 88.4% | | |
| Research and development | 523.4% | | 15452.6% | | | |
| General and administrative | | | | | 61.2% | |
| EBITDA | -903.5% | -174.0% | -28995.1% | -187.8% | -158.6% | |
| Depreciation | 2.2% | | 18.2% | | | |
| EBIT | -905.7% | -174.0% | -29013.3% | -187.8% | -158.6% | |
| Pre-tax income | -888.9% | -170.8% | -30853.0% | -199.7% | -171.9% | |
| Income taxes | 3.5% | 0.7% | 0.0% | 0.0% | 0.0% | |
| Net income | -892.4% | -171.5% | -30853.0% | -199.7% | -171.9% | |
|